Analyst Comment
Aiforia to five new hospitals in France
Summary
- Aiforia has been selected as an AI partner for the PROSTIA project, expanding its prostate cancer diagnostics solution to five new AP-HP pathology sites in Paris.
- The project, part of the France 2030 program, aims to integrate AI into routine pathology workflows, potentially influencing France's pathology reimbursement systems.
- The collaboration with AP-HP, Europe's largest hospital system, supports Aiforia's growth estimates and strengthens its position in the digital pathology market.
- The analyst expects Aiforia to continue strong growth this year and in 2027, with projected revenue reaching 7.9 MEUR.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 04/17/2026 at 07:32 am EEST
Aiforia announced on Thursday that it had been selected as an AI partner for the French PROSTIA project. With this agreement, the company's prostate cancer diagnostics solution will be implemented in five new Assistance Publique–Hôpitaux de Paris (AP-HP) pathology sites, in addition to the previous two. We believe the two-year project includes the possibility of longer-term use of Aiforia's solutions in these hospitals for prostate cancer and potentially for other uses later on. The release supports our growth estimates for the coming years.
Expansion of Europe's largest hospital system
The expansion of the collaboration within AP-HP is a good reference for Aiforia, as it represents one of Europe's first large-scale implementations of AI in routine pathology. Through this project, AP-HP will analyze all of the approximately 3,000 prostate biopsy cases examined annually using Aiforia's AI technology. The agreement is a continuation of the collaboration initiated in 2024 at Bicêtre and Saint-Louis hospitals. PROSTIA is a two-year project funded by Bpifrance as part of the national France 2030 program. Aiforia has successfully and efficiecntly won customers in recent years. The new collaboration partly supports the company's position in the emerging digital pathology market.
The market is gradually maturing
The key goal of the PROSTIA project is to evaluate the medical, operational, and economic impacts of integrating AI into routine pathology workflows. The evaluation lays the groundwork for the inclusion of AI solutions in France's pathology reimbursement systems. In our view, the opening of reimbursement systems for AI-powered diagnostics is one of the most significant long-term drivers for the digitalization of the entire industry and for the widespread demand for Aiforia's solutions.
Although clinical customer wins have previously been slow to translate into revenue, the expansion of a large player like AP-HP strengthens our confidence that the market is gradually maturing towards routine use. We expect the company to continue strong growth this year and in 2027, when we estimate revenue to grow to 7.9 MEUR.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures08/03
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | 24.0 % | 45.0 % | 55.0 % |
| EBIT (adj.) | -11.2 | -9.2 | -8.3 |
| EBIT-% (adj.) | -316.3 % | -178.7 % | -104.7 % |
| EPS (adj.) | -0.38 | -0.25 | -0.19 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
